Given that poor clinical prognosis was associated with elevated TLR3 expression in breast cancer,22 it is possible that tumor cells with high levels of TLR3 expression and activation of NF-κB and Wnt/β-catenin pathways are more resistant to conventional therapies and easy to relapse. Here, NFKB1 is linked to breast cancer.